GSK teams up with US Money to found new Biotech

26/05/2016 - 2 minutes

GSK and Avalon Ventures are having success with the Biotechs created under their collaboration. Sitari Pharmaceuticals and Silarus Therapeutics have achieved their first milestones, and there’s a 8th Biotech in the making.

gsk_avalon_ventures_pdi_therapeuticsAs part of its innovation hunting in the US, English big Pharma GSK had struck a collaboration with Avalon Ventures and formed an ‘undercover incubator’ of sorts.

This incubator is COI Pharmaceuticals, a ‘venture-pharma entity’ that provides R&D infrastructures and industry mentors to create new Biotechs.

Now, the collaboration is reaping some successes. The first two Biotechs created by the programme have reached their first milestones – establishing a plan to identify a clinical candidate.

The first is Sitari Pharmaceuticals, which is developing treatments for celiac disease. Its therapeutic approach targets Transglutaminase 2 (TG2), an enzyme that is thought to play an important role in this autoimmune disease.

The other is Silarus Therapeutics, which targets erythroferrone.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!